Sequential pathways of testing after first-trimester screening for trisomy 21

Obstetrics and Gynecology

Volumn 104, Issue 4, 2004, Pages 661-666

  Platt, Lawrence D ^a   Greene, Naomi ^a   Johnson, Anthony ^a   Zachary, Julia ^a   Thom, Elizabeth ^a   Krantz, David ^a   Simpson, Joe Leigh ^a   Silver, Richard K ^a   Snijders, Rosalinde J M ^a   Goetzl, Laura ^a   Pergament, Eugene ^a   Filkins, Karen ^a   Mahoney, Maurice J ^a   Hogge, W Allen ^a   Wilson, R Douglas ^a   Mohide, Patrick ^a   Hershey, Douglas ^a   MacGregor, Scott ^a   Bahado Singh, Ray ^a   Jackson, Laird G ^a   Wapner, Ronald ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A; ESTRADIOL;

ADULT; ALGORITHM; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MATERNAL SERUM; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; RISK ASSESSMENT; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 21; BLOOD; CANADA; CLINICAL TRIAL; DECISION TREE; DOWN SYNDROME; EVALUATION; METHODOLOGY; MULTICENTER STUDY; PREDICTION AND FORECASTING; PREGNANCY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ADULT; ALGORITHMS; ALPHA-FETOPROTEINS; CANADA; CHORIONIC GONADOTROPIN; COHORT STUDIES; DECISION TREES; DOWN SYNDROME; ESTRADIOL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 7944220040     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000139832.79658.b9     Document Type: Article

References (19)

1. Hobbins JC, Lezotte DC, Persutte WH, DeVore GR, Benacerraf BR, Nyberg DA, et al. An 8-center study to evaluate the utility of mid-term genetic sonograms among high-risk pregnancies. J Ultrasound Med 2003;22:33-8.
2. Cuckle H. Established markers in second trimester maternal serum. Early Hum Dev 1996;47(suppl):27-9.
3. Wald NJ, Huttly WJ, Hackshaw A. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-6.
4. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-9.
5. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998;352:343-6.
6. Pandya PP, Brizot ML, Kuhn P, Snijders RJ, Nicolaides KH. First trimester fetal nuchal translucency thickness and risk for trisomies. Obstet Gynecol 1994;84:420-3.
7. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 1995;102:957-62.
8. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol 1996;174:612-6.
9. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol. 2000;96:207-13.
10. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-7.
11. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-13.
12. Snijders RJ, Thom EA, Zachary JM, Platt LD, Greene N, Jackson LG, et al. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002;19:353-9.
13. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998;338:955-61.
14. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-77.
15. Kadir RA, Economides DL. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 1997;9:244-7.
16. Thilaganathan B, Slack A, Wathen NC. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down syndrome. Ultrasound Obstet Gynecol 1997;10:261-4.
17. Rozenberg P, Malagrida L, Cuckle H, Durand-Zaleski I, Nisand I, Audibert F, et al. Down's syndrome screening with nuchal translucency at 12(+-0)-14(+-0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study. Hum Reprod 2002;17:1093-8.
18. Cuckle H. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995;15:1057-65.
19. Rhoads GG, Jackson LG, Schlesselman SE, de la Cruz FF, Desnick RJ, Golbus MS, et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetics abnormalities. N Engl J Med 1989;320:609-17.